Literature DB >> 17234579

Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion.

Marco Timmer1, Konstantin Cesnulevicius, Christian Winkler, Julia Kolb, Esther Lipokatic-Takacs, Julia Jungnickel, Claudia Grothe.   

Abstract

Basic fibroblast growth factor (FGF-2) is involved in the development and maintenance of the nervous system. Exogenous administration of FGF-2 increased dopaminergic (DA) graft survival in different animal models of Parkinson's disease. To study the physiological function of the endogenous FGF-2 system, we analyzed the nigrostriatal system of mice lacking FGF-2, mice overexpressing FGF-2, and FGF-receptor-3 (FGFR3)-deficient mice both after development and after 6-hydroxydopamine lesion. FGFR3-deficient mice (+/-) displayed a reduced number of DA neurons compared with the respective wild type. Whereas absence of FGF-2 led to significantly increased numbers of DA neurons, enhanced amount of the growth factor in mice overexpressing FGF-2 resulted in less tyrosine hydroxylase expression and a reduced DA cell density. The volumes of the substantia nigra were enlarged in both FGF-2(-/-) and in FGF-2 transgenic mice, suggesting an important role of FGF-2 for the establishment of the proper number of DA neurons and a normal sized substantia nigra during development. In a second set of experiments, the putative relevance of endogenous FGF-2 after neurotoxin application was investigated regarding the number of rescued DA neurons after partial 6-OHDA lesion. Interestingly, the results after lesion were directly opposed to the results after development: significantly less DA neurons survived in FGF-2(-/-) mice compared with wild-type mice. Together, the results indicate that FGFR3 is crucially involved in regulating the number of DA neurons. The lack of FGF-2 seems to be (over)compensated during development, but, after lesion, compensation mechanisms fail. The transgenic mice showed that endogenous FGF-2 protects DA neurons from 6-OHDA neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234579      PMCID: PMC6672785          DOI: 10.1523/JNEUROSCI.4493-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  102 in total

1.  The high molecular weight fibroblast growth factor-2 isoforms (21,000 mol. wt and 23,000 mol. wt) mediate neurotrophic activity on rat embryonic mesencephalic dopaminergic neurons in vitro.

Authors:  C Grothe; A Schulze; I Semkova; F Müller-Ostermeyer; A Rege; K Wewetzer
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons.

Authors:  A C Granholm; M Reyland; D Albeck; L Sanders; G Gerhardt; G Hoernig; L Shen; H Westphal; B Hoffer
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

3.  Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.

Authors:  D L Miller; S Ortega; O Bashayan; R Basch; C Basilico
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

Authors:  K Parain; M G Murer; Q Yan; B Faucheux; Y Agid; E Hirsch; R Raisman-Vozari
Journal:  Neuroreport       Date:  1999-02-25       Impact factor: 1.837

6.  Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats.

Authors:  L Studer; V Tabar; R D McKay
Journal:  Nat Neurosci       Date:  1998-08       Impact factor: 24.884

7.  Identification of a novel FGF, FGF-21, preferentially expressed in the liver.

Authors:  T Nishimura; Y Nakatake; M Konishi; N Itoh
Journal:  Biochim Biophys Acta       Date:  2000-06-21

8.  Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts.

Authors:  A Rödter; C Winkler; M Samii; G Nikkhah
Journal:  Cell Transplant       Date:  2000 Mar-Apr       Impact factor: 4.064

9.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

Authors:  H Shimura; N Hattori; S i Kubo; Y Mizuno; S Asakawa; S Minoshima; N Shimizu; K Iwai; T Chiba; K Tanaka; T Suzuki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

10.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.

Authors:  M H Xie; I Holcomb; B Deuel; P Dowd; A Huang; A Vagts; J Foster; J Liang; J Brush; Q Gu; K Hillan; A Goddard; A L Gurney
Journal:  Cytokine       Date:  1999-10       Impact factor: 3.861

View more
  35 in total

Review 1.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

2.  Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease.

Authors:  Rosario Sanchez-Pernaute; Hyojin Lee; Michaela Patterson; Casper Reske-Nielsen; Takahito Yoshizaki; Kai C Sonntag; Lorenz Studer; Ole Isacson
Journal:  Brain       Date:  2008-07-22       Impact factor: 13.501

3.  ES cell-derived renewable and functional midbrain dopaminergic progenitors.

Authors:  Sangmi Chung; Jung-Il Moon; Amanda Leung; Daniel Aldrich; Stefan Lukianov; Yui Kitayama; Sara Park; Yan Li; Vadim Y Bolshakov; Thomas Lamonerie; Kwang-Soo Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

4.  Expression of early developmental markers predicts the efficiency of embryonic stem cell differentiation into midbrain dopaminergic neurons.

Authors:  Ahmad Salti; Roxana Nat; Sonya Neto; Zoe Puschban; Gregor Wenning; Georg Dechant
Journal:  Stem Cells Dev       Date:  2012-09-20       Impact factor: 3.272

5.  Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effect of bFGF in the 6-OHDA-Induced Parkinson's Disease Model.

Authors:  Pingtao Cai; Jingjing Ye; Jingjing Zhu; Dan Liu; Daqing Chen; Xiaojie Wei; Noah R Johnson; Zhouguang Wang; Hongyu Zhang; Guodong Cao; Jian Xiao; Junming Ye; Li Lin
Journal:  Aging Dis       Date:  2016-01-17       Impact factor: 6.745

Review 6.  Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives.

Authors:  Jesse V Veenvliet; Marten P Smidt
Journal:  Cell Mol Life Sci       Date:  2014-07-27       Impact factor: 9.261

7.  Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease.

Authors:  Xiaojie Wei; Songbin He; Zhouguang Wang; Jiamin Wu; Jinjing Zhang; Yi Cheng; Jie Yang; Xinlong Xu; Zaifeng Chen; Junmin Ye; Li Chen; Li Lin; Jian Xiao
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

Review 8.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  NMR-Based Metabolomics Reveal a Recovery from Metabolic Changes in the Striatum of 6-OHDA-Induced Rats Treated with Basic Fibroblast Growth Factor.

Authors:  Hong Zheng; Liangcai Zhao; Huanhuan Xia; Cuicui Xu; Dan Wang; Kun Liu; Li Lin; Xiaokun Li; Zhihan Yan; Hongchang Gao
Journal:  Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.590

10.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.